Opsoclonus-myoclonus (OM) is a paraneoplastic syndrome of probable autoimmune origin. Despite current therapies aimed at decreasing autoantibody formation, OM is difficult to control and may impact long-term neurologic outcome. We present a case of a 19-month-old patient who initially presented with OM, neuroblastoma and a constitutional cytogenetic abnormality t(5;12)(q11.2;q15). The patient's OM was recalcitrant to conventional therapies, but showed significant improvement following treatment with rituximab. Pediatr Blood Cancer 2008;50:370-371. (c) 2006 Wiley-Liss, Inc.
Response to rituximab in a child with neuroblastoma and opsoclonus-myoclonus. Publishing Authors By Initials
Response to rituximab in a child with neuroblastoma and opsoclonus-myoclonus. Journal Published:
PUBLICATION TYPE: Journal Article
Journal: Pediatric blood & cancer
VOLUME: 50
Page Numbers: 370-1
Journal Abbreviation:
ISSN: 1545-5017
DAY: 12
MONTH: Feb
YEAR: 2008
Response to rituximab in a child with neuroblastoma and opsoclonus-myoclonus. Information
Number of References:
LANGUAGE: eng
NlmUniqueID: 101186624
Response to rituximab in a child with neuroblastoma and opsoclonus-myoclonus. Keywords Mesh Terms:
KEYWORDS:
MESH TERMS:
Chemical & Substance for Abstract: Response to rituximab in a child with neuroblastoma and opsoclonus-myoclonus. Information
Substance Name:
Registry Number:
Grant and Affiliation Information for Response to rituximab in a child with neuroblastoma and opsoclonus-myoclonus.
AFFILIATION: Department of Pediatrics, Division of Pediatric Hematology-Oncology, University of North Carolina School of Medicine, Chapel Hill, North Carolina.
Country: United States
AGENCY:
GRANT:
ACRONYM:
MEDLINETA: Pediatr Blood Cancer
REFSOURCE:
DATABASENAME:
ACCESSION NUMBER:
Number Hits: 0
Response to rituximab in a child with neuroblastoma and opsoclonus-myoclonus Related Publications